glp-1 and liver Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) non-alcoholic steatohepatitis (NASH) Current Status of Glucagon-like Peptide-1

Its primary outcomes measure is time to first occurrence of any component event of a composite endpoint comprising all-cause death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or heart failure events that result in hospitalization or urgent hospital visits

Copper (as Albion Copper Bisglycinate Chelate)

Learn what evidence shows about colorectal cancer risk.

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)

Discover personalized Ozempic dosing approaches now!

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for weight loss, and supplements for heart health.